Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd. filed a Form 6-K highlighting a new peer-reviewed article that reviews the broad therapeutic potential of its lead A3 adenosine receptor (A3AR) agonists, Piclidenoson and Namodenoson, across multiple major diseases. The article, published in the Biomolecules journal, compiles data from the company and independent research groups worldwide, which the company views as important scientific validation of its A3AR platform.
The filing reiterates that Namodenoson is in Phase 3 development for hepatocellular carcinoma, Phase 2 for pancreatic cancer, and Phase 2b for MASH, while Piclidenoson is in a pivotal Phase 3 study for psoriasis. It also notes Orphan Drug and Fast Track designations for Namodenoson, and states that Can-Fite’s drug candidates have shown an excellent safety profile in more than 1,600 patients to date.
Can-Fite BioPharma Ltd. is highlighting its late-stage clinical pipeline and licensing opportunities at the BIO International Convention 2026, held June 22–25, 2026 in San Diego. The company plans partnering meetings with pharmaceutical and biotech firms to discuss licensing and commercialization of its clinical-stage assets.
The lead liver drug Namodenoson is in a pivotal Phase III study for advanced hepatocellular carcinoma, a Phase IIb trial for MASH, and a Phase IIa study in pancreatic cancer. Piclidenoson is in a pivotal Phase III trial for psoriasis, with preparatory work underway for a Phase II study in Lowe Syndrome. A third candidate, CF602, has shown efficacy for erectile dysfunction.
Can-Fite’s A3 adenosine receptor platform has shown a favorable safety profile in more than 1,600 treated patients. The company reports multiple regional licensing deals that have generated approximately $20 million in upfront and milestone payments, with potential for additional milestones and royalties.
Can-Fite BioPharma Ltd. reported that its CEO, CFO and COO, Motti Farbstein, received a grant of options to purchase 24,000 Ordinary Shares on an award basis. These options have an exercise price of $2.043 per share and expire on June 4, 2036.
The options will vest in sixteen equal quarterly installments starting on September 4, 2026 and ending on April 6, 2030, contingent on his continued service. Following this grant, Farbstein holds 33,132 options to purchase Ordinary Shares directly.
Can-Fite BioPharma Ltd. reported that Chief Scientific Officer Pnina Fishman received a grant of 24,000 options to purchase ordinary shares. The options have an exercise price of $2.043 per share and bring her reported option holdings to 34,299 options after the grant.
The options vest in 16 equal quarterly installments from September 4, 2026 through April 6, 2030, conditional on continued service. To qualify for tax benefits under Section 102 of the Israeli Tax Ordinance, the securities are registered in a trustee’s name, and the exercise price was converted from NIS 5.94 using a NIS 2.908 = $1.00 exchange rate.
Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, reports that its Annual General Meeting of Shareholders held on June 4, 2026 approved all five proposals presented to shareholders. These proposals were previously detailed in the company’s Notice and Proxy Statement dated April 23, 2026, which had been furnished to the SEC on Form 6-K.
Can-Fite BioPharma Ltd. furnished a corporate update highlighting early clinical and mechanistic data for its drug namodenoson in pancreatic cancer. In an ongoing Phase 2a monotherapy study, enrollment is complete and several patients have shown prolonged disease control, including one patient remaining on therapy and follow-up for about 16 months.
The company emphasizes namodenoson’s differentiated mechanism, noting preclinical anti-tumor activity via modulation of RAS, Wnt/β-catenin and NF-κB signaling pathways, which are relevant in RAS-driven malignancies such as pancreatic ductal adenocarcinoma. Namodenoson is a selective A3 adenosine receptor agonist with a reported favorable safety profile and Orphan Drug Designation for pancreatic cancer.
Can-Fite also recaps its broader pipeline. Piclidenoson is in a pivotal Phase 3 psoriasis trial, while namodenoson is in a Phase III trial for hepatocellular carcinoma and a Phase 2b trial for MASH. Across programs, the company reports clinical experience in over 1,600 patients to date.
Can-Fite BioPharma Ltd. held its 2026 Annual General Meeting of Shareholders on May 28, 2026, but the meeting was adjourned because there were not enough shareholders present to meet the required quorum. The meeting is scheduled to reconvene on June 4, 2026 at 3:00 p.m. Israel time at the company’s offices in Ramat Gan, Israel.
Can-Fite BioPharma Ltd. furnished a report highlighting a new peer-reviewed publication on its lead drug candidate Piclidenoson in canine osteoarthritis. The article in Frontiers in Veterinary Science describes a study where oral Piclidenoson produced statistically significant improvements in mobility and pain in dogs, with a favorable safety profile.
Piclidenoson is being developed for veterinary use by Vetbiolix under a licensing agreement potentially valued at up to $325 million in upfront, milestone and royalty payments, and is currently in an advanced Phase 2 clinical study in dogs. Can-Fite also reiterates its broader clinical pipeline, including Piclidenoson in psoriasis Phase 3 trials and Namodenoson in multiple Phase II/III studies in liver and oncology indications, all supported by safety experience in over 1,600 patients.
Can-Fite BioPharma Ltd. reported encouraging Phase 2a results for Namodenoson in advanced pancreatic cancer and plans a Phase 2b study combining the drug with immunotherapy. The Phase 2a trial showed a favorable safety profile, treatment extending beyond 16 months in some patients, stable disease in over 30% of evaluable patients, and 35% of patients remaining on therapy and follow up. The company intends to discuss the Phase 2b study design and potential partnerships with leading oncology companies at the BIO International Convention. Namodenoson has Orphan Drug Designation from the U.S. FDA for pancreatic cancer and is also in trials for liver cancer and MASH.
Can-Fite BioPharma Ltd. reported positive Phase 2a data for its drug namodenoson in advanced pancreatic cancer. In this fully enrolled, 20-patient open-label study, namodenoson showed a favorable safety profile and preliminary signs of durable disease stabilization in heavily pretreated patients.
About 35% of patients remain on therapy, including one treated for more than 16 months, suggesting potential for longer-term benefit in this difficult-to-treat setting. The trial met its primary safety endpoint, with no new safety signals and consistency with prior namodenoson experience. Full efficacy analyses, including progression-free and overall survival, are planned, with top-line results expected to be presented at an upcoming clinical conference.